Advertisement

Quantification of Docetaxel in Serum Using Turbulent Flow Liquid Chromatography Electrospray Tandem Mass Spectrometry (TFC-HPLC-ESI-MS/MS)

  • Christopher A. Crutchfield
  • Mark A. Marzinke
  • William A. ClarkeEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1383)

Abstract

Docetaxel is a second-generation taxane and is used clinically as an anti-neoplastic agent in cancer chemotherapy via an anti-mitotic mechanism. Its efficacy is limited to a narrow therapeutic window. Inappropriately high concentrations may cause erythema, fluid retention, nausea, diarrhea, and neutropenia. As a result, dosing recommendations have changed from high dosage loading every 3 weeks to lower dosage loading weekly. We describe a method that can be used for therapeutic drug monitoring of docetaxel levels using turbulent flow liquid chromatography electrospray tandem mass spectrometry (TFC-HPLC-ESI-MS/MS). The method is rapid, requiring only 6.3 min per analytical run following a simple protein crash. The method requires only 100 μL of serum. Concentrations of docetaxel were quantified by a calibration curve relating the peak-area ratio of docetaxel to a deuterated internal standard (docetaxel-D9). The method was linear from 7.8 to 1000 ng/mL, with imprecision ≤6.2 %.

Key words

Docetaxel Anti-neoplastic Turbulent flow liquid chromatography electrospray tandem mass spectrometry 

References

  1. 1.
    Salminen E, Bergman M, Huhtala S, Ekholm E (1999) Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study. J Clin Oncol 17:1127PubMedGoogle Scholar
  2. 2.
    Saloustros E, Georgoulias V (2008) Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 8:1207–1222CrossRefPubMedGoogle Scholar
  3. 3.
    Gilbert DC, Parker C (2005) Docetaxel for the treatment of prostate cancer. Future Oncol 1:307–314CrossRefPubMedGoogle Scholar
  4. 4.
    Burstein HJ, Manola J, Younger J et al (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212–1219PubMedGoogle Scholar
  5. 5.
    Clarke DSJ, Rivory LP (2012) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99–114CrossRefGoogle Scholar
  6. 6.
    Marzinke MA, Breaud AR, Clarke W (2013) The development and clinical validation of a turbulent-flow liquid chromatography-tandem mass spectrometric method for the rapid quantitation of docetaxel in serum. Clin Chim Acta 417:12–18CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Christopher A. Crutchfield
    • 1
  • Mark A. Marzinke
    • 1
  • William A. Clarke
    • 1
    Email author
  1. 1.Department of PathologyThe Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations